Oppenheimer Reiterates Outperform and PT of $21 on MedAssets
Oppenheimer reiterated its Outperform rating on MedAssets (NASDAQ: MDAS). At the same time, Oppenheimer left its price target on the company's stock unchanged at $21. In today's trading, MedAssets added 0.04% to its value to trade around $13.20.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.